国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2011年
5期
573-576
,共4页
刘幸清%胡旭东%何仁亮%张文礼%吴亚彬%凌晨
劉倖清%鬍旭東%何仁亮%張文禮%吳亞彬%凌晨
류행청%호욱동%하인량%장문례%오아빈%릉신
帕瑞昔布%吻合器痔上粘膜环切术%超前镇痛
帕瑞昔佈%吻閤器痔上粘膜環切術%超前鎮痛
파서석포%문합기치상점막배절술%초전진통
Parecoxib%Procedure for prolapse and hemorrhoids%Preemptive analgesia
目的 探讨帕瑞昔布超前镇痛刚于吻合器痔上粘膜环切术患者的安全性和有效性.方法 70例ASA Ⅰ~Ⅱ级择期行吻合器痔上粘膜环切术患者,随机分为帕瑞昔布组和对照组.帕瑞昔布组于麻醉前5分钟静脉注射40mg帕瑞昔布作为超前镇痛,对照组则静脉给予生理盐水5 ml.分别于术后4、8、12、24小时观察并记录两组病人镇痫药使用情况和不良反应,以视觉模拟评分(VAS)评价其镇痛效果,以舒适评分标准(BCS)判定病人满意程度.结果 术后镇痫药使用例数帕瑞昔布组明显少于对照组(2:7,P<0.05).术后4、8、12、24小时VAS评分帕瑞昔布组明显低于对照组[(1.0±0.6,2.6±0.6,3.6±0.5,1.8±0.6 ):( 1.4±0.7,3.1±0.8,4.1±0.7,2.2±0.8),P<0.05],BCS评分帕瑞昔布组显著高于对照组(3.5±0.5,2.4±0.4,1.7±0.5,2.9±0.5):(3.1±0.6,2.0±0.5,1.2±0.6,2.6±0.5),P<0.05].两组病人术后不良反应差异无显著性(P>0.05).结论 帕瑞昔布超前镇痛用于吻合器痔上粘膜环切术患者,可明显减少术后疼痛,病人满意程度高,不良反应少,安全可靠.
目的 探討帕瑞昔佈超前鎮痛剛于吻閤器痔上粘膜環切術患者的安全性和有效性.方法 70例ASA Ⅰ~Ⅱ級擇期行吻閤器痔上粘膜環切術患者,隨機分為帕瑞昔佈組和對照組.帕瑞昔佈組于痳醉前5分鐘靜脈註射40mg帕瑞昔佈作為超前鎮痛,對照組則靜脈給予生理鹽水5 ml.分彆于術後4、8、12、24小時觀察併記錄兩組病人鎮癇藥使用情況和不良反應,以視覺模擬評分(VAS)評價其鎮痛效果,以舒適評分標準(BCS)判定病人滿意程度.結果 術後鎮癇藥使用例數帕瑞昔佈組明顯少于對照組(2:7,P<0.05).術後4、8、12、24小時VAS評分帕瑞昔佈組明顯低于對照組[(1.0±0.6,2.6±0.6,3.6±0.5,1.8±0.6 ):( 1.4±0.7,3.1±0.8,4.1±0.7,2.2±0.8),P<0.05],BCS評分帕瑞昔佈組顯著高于對照組(3.5±0.5,2.4±0.4,1.7±0.5,2.9±0.5):(3.1±0.6,2.0±0.5,1.2±0.6,2.6±0.5),P<0.05].兩組病人術後不良反應差異無顯著性(P>0.05).結論 帕瑞昔佈超前鎮痛用于吻閤器痔上粘膜環切術患者,可明顯減少術後疼痛,病人滿意程度高,不良反應少,安全可靠.
목적 탐토파서석포초전진통강우문합기치상점막배절술환자적안전성화유효성.방법 70례ASA Ⅰ~Ⅱ급택기행문합기치상점막배절술환자,수궤분위파서석포조화대조조.파서석포조우마취전5분종정맥주사40mg파서석포작위초전진통,대조조칙정맥급여생리염수5 ml.분별우술후4、8、12、24소시관찰병기록량조병인진간약사용정황화불량반응,이시각모의평분(VAS)평개기진통효과,이서괄평분표준(BCS)판정병인만의정도.결과 술후진간약사용례수파서석포조명현소우대조조(2:7,P<0.05).술후4、8、12、24소시VAS평분파서석포조명현저우대조조[(1.0±0.6,2.6±0.6,3.6±0.5,1.8±0.6 ):( 1.4±0.7,3.1±0.8,4.1±0.7,2.2±0.8),P<0.05],BCS평분파서석포조현저고우대조조(3.5±0.5,2.4±0.4,1.7±0.5,2.9±0.5):(3.1±0.6,2.0±0.5,1.2±0.6,2.6±0.5),P<0.05].량조병인술후불량반응차이무현저성(P>0.05).결론 파서석포초전진통용우문합기치상점막배절술환자,가명현감소술후동통,병인만의정도고,불량반응소,안전가고.
Objective To explore the efficacy and safety of preemptive analgesia with parecoxib in procedure for prolapse and hemorrhoids (PPH). Methods 70 ASA Ⅰ - Ⅱ patients scheduled for PPH were randomly assigned to receive intravenous parecoxib of 40 mg 5 min before anesthesia as preemptive analgesia (parecoxib group), or 0.9% NS of 5 ml (control group). The adverse reactions and use of analgetics were recorded postoperatively at hours 4, 8, 12, and 24. The analgetic effect was measured with VAS and the satisfactory degree in the patients was evaluated with BCS. Results The number of patients using supplementary analgetics after the procedure was smaller in the parecoxib group than in the control group (2 vs. 7,P<0.05=. The VAS scale was lower in the parecoxib group than in the control group at the four time points (1.0 ± 0.6vs 1.4 ± 0.7, 2.6 ± 0.6vs3.1 ± 0.8, 3.6 ± 0.5 vs4.1 ± 0.7, and 1.8 ± 0.6 vs2.2 ± 0.8; P< 0.05=, whereas the BCS scale was higher (3.5 ± 0.5 vs 3.1 ± 0.6, 2.4 ± 0.4 vs 2.0 ± 0.5, 1.7 ± 0.5 vs 1.2 ± 0.6, and 2.9 ± 0.5 vs 2.6 ± 0.5, P< 0.05). There was no significant difference in adverse reactions between the two groups (P> 0.05). Conclusions Preemptive analgesia with parecoxib in procedure for prolapse and hemorrhoids can obviously relieve postsurgical pain with higher satisfaction and fewer adverse reactions. It is safe and reliable.